Track topics on Twitter Track topics that are important to you
To see if people with oropharyngeal cancer can be treated with E7 T cells before getting standard treatment.
People ages 18-65 with Stage II or III HPV-16 associated oropharyngeal cancer
Participants will be screened with:
Blood and heart tests
Tumor tissue: If this is not available, they will have a biopsy.
Participants will have a catheter inserted into a vein in the chest.
Participants will have leukapheresis. Blood will be removed through a needle in one arm, move through a machine that takes out the white blood cells, then returned through a needle in the other arm. The white blood cells will be modified in the lab.
Participants will be admitted to the hospital a week before treatment. They will get chemotherapy and then the E7 TCR cells through the catheter. They will recover in the hospital for 7-12 days. They will get a drug through the catheter for 5 days. They may get an injection every day.
Participants will have visits every 2 weeks. This will continue until their disease goes away or the treatment stops working. Then they will have blood tests at months 3, 6, and 12 in the first year. Then they will have annual physical exams for 5 years. Then they will complete annual questionnaires for 10 years.
- Human papillomavirus (HPV)+ oropharyngeal cancer is an increasingly common type of cancer that frequently affects young patients.
- The treatment for locoregionally advanced cancer carries substantial life-long morbidity.
- Although the overall prognosis for HPV+ oropharyngeal cancer is favorable, about 20 percent of patients with stage II disease and 35 percent of patients with stage III disease will die within five years.
- Induction therapy is an area of active study in this type of cancer. The aims of induction therapy are to reduce the risk of disease recurrence and potentially to permit the study of de-intensified definitive treatment of locoregional disease.
- E7 TCR T cells, administered as a single infusion, have demonstrated safety and clinical activity in treatment-refractory metastatic HPV+ cancers.
-To determine the feasibility of systemic treatment with E7 TCR T cells for stage II or stage III HPV+ oropharyngeal cancer.
- Patients greater than or equal to 18 years old and less than or equal to 66 years old with stage II or stage III HPV+ oropharyngeal cancer.
- The cancer must be HPV16+ and patient must be HLA-A 02:01+ HLA type.
- Patients must be treatment-naive.
- This is a phase II, single arm, feasibility study of induction E7 TCR T cell therapy.
- Patients will receive a conditioning regimen of cyclophosphamide and fludarabine, a single infusion of E7 TCR T cells, and systemic aldesleukin.
- Patients will be referred for standard of care definitive therapy (chemoradiation or surgery) at the time of maximum tumor response
National Institutes of Health Clinical Center
Not yet recruiting
National Institutes of Health Clinical Center (CC)
Published on BioPortfolio: 2019-07-16T10:38:51-0400
Since other genital infections enhance HIV susceptibility by inducing inflammation, the investigators study the relationship between the vaginal microbiota composition and the risk of HPV ...
The purpose of this study is to determine if maternal infection with human papillomavirus (HPV) is associated with pregnancy complications including spontaneous preterm delivery (sPTD), se...
This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.
Vertical transmission of human papillomavirus (HPV) 6/11 leads to infection in the lower airway of neonates. The presence of HPV 6/11 may later cause juvenile onset recurrent respiratory p...
The purpose of this study is to determine the safety of and immune response to a new human papillomavirus (HPV) vaccine in HIV infected children between the ages of 7 and 12 years.
The President's Cancer Panel released a report in 2014 calling for communication strategies to promote the human papillomavirus vaccine among males and females. The purpose of this study was to (1) es...
Since other genital infections enhance HIV susceptibility by inducing inflammation and evidence suggests that the vaginal microbiome plays a functional role in the persistence or regression of high-ri...
Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 ...
Persistence of high-risk human papillomavirus (hr-HPV) infections is the most critical risk factor for cervical intraepithelial neoplasia (CIN) and cervical cancer (CC). Treatment of persistent oncoge...
Despite being preventable, cervical cancer remains a major health concern among women. Persistent Human Papillomavirus (HPV) and other viral co-infections may influence cervical dysplasia. We determin...
Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.
ONCOGENE PROTEINS from papillomavirus that deregulate the CELL CYCLE of infected cells and lead to NEOPLASTIC CELL TRANSFORMATION. Papillomavirus E7 proteins have been shown to interact with various regulators of the cell cycle including RETINOBLASTOMA PROTEIN and certain cyclin-dependent kinase inhibitors.
A type of XIPAPILLOMAVIRUS causing alimentary carcinoma in cattle. It is related to Bovine papillomavirus 3.
A type of human papillomavirus especially associated with malignant tumors of the genital and RESPIRATORY MUCOSA.
Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells. In vertebrates, it is composed of blo...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...